Ipsen Gives Genfit Liver Drug New Lease Of Life

Pays €120m Upfront For Elafibranor Rights

The French biotech was firmly on the ropes last year after elafibranor joined the long list of failures for NASH but the promise it has shown in primary biliary cholangitis has persuaded Ipsen to part with a hefty upfront fee.

liver
• Source: Archive

It is definitely the season to be jolly for Genfit SA after signing a lucrative licensing deal with fellow French firm Ipsen SA for elafibranor for the rare liver disease primary biliary cholangitis, some 18 months after the compound was discontinued as a potential treatment for NASH.

The deal has taken observers by surprise not least because of the terms that Genfit has secured. Ipsen will pay...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category